AVNS (Avanos Medical) 5-Year EBITDA Growth Rate: 0.00% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AVNS Avanos Medical Inc AVNS
40 GF Score
Price $24.99
GF Value $19.31
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Avanos Medical 5-Year EBITDA Growth Rate?

Avanos Medical AVNS +0.04% 40 5-Year EBITDA Growth Rate is 0.00% as of Mar. 2026. GuruFocus rates AVNS with a GF Score™ of 40/100 and a GF Value™ of $19.31 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Avanos Medical's EBITDA per Share for the three months ended in Mar. 2026 was $0.41.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Avanos Medical was 34.10% per year. The lowest was -809.10% per year. And the median was -32.45% per year.

Avanos Medical  (NYSE:AVNS) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Avanos Medical 5-Year EBITDA Growth Rate Related Terms

AVNS vs TNDM, IRMD, AORT: 5-Year EBITDA Growth Rate Comparison

For the Medical Devices subindustry, Avanos Medical's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avanos Medical 5-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Avanos Medical's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Avanos Medical's 5-Year EBITDA Growth Rate falls into.


AVNS
40GF Score
Avanos Medical Inc AVNS
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Avanos Medical 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 0.00% mean?
Avanos Medical (AVNS) has a 5-Year EBITDA Growth Rate of 0.00% as of Mar. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Avanos Medical and its competitors.
Is Avanos Medical's 5-Year EBITDA Growth Rate too high?
Avanos Medical's current 5-Year EBITDA Growth Rate is 0.00%. Overall, Avanos Medical has a GF Score™ of 40/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Avanos Medical's 5-Year EBITDA Growth Rate compare to TNDM and IRMD?
Avanos Medical's 5-Year EBITDA Growth Rate of 0.00% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
A good 5-Year EBITDA Growth Rate depends on the Medical Devices & Instruments industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Avanos Medical and its competitors. Avanos Medical's current 5-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avanos Medical stock overvalued right now?
Based on GuruFocus' analysis, Avanos Medical (AVNS) is currently considered Modestly Overvalued. The stock's GF Value™ is $19.31, compared to a current price of $24.99 — trading 29.4% above its estimated fair value. The current 5-Year EBITDA Growth Rate is 0.00%. Avanos Medical's overall GF Score™ is 40/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Avanos Medical (AVNS), the current 5-Year EBITDA Growth Rate is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Avanos Medical (AVNS) Overvalued in 2026?

Based on GuruFocus' analysis, Avanos Medical stock appears to be overvalued. The current stock price of $24.99 is trading 29.4% above its estimated GF Value™ of $19.31. GuruFocus considers Avanos Medical to be Modestly Overvalued.

Key valuation signals for AVNS:

  • 5-Year EBITDA Growth Rate: 0.00%
  • GF Value™: $19.31 vs. price of $24.99 (29.4% above fair value)
  • GF Score™: 40/100 with 5 warning signs

No single metric tells the full story. See the AVNS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Avanos Medical Business Description

Other Exchanges 8HH:Germany
Address 5405 Windward Parkway, Suite 100 South, Alpharetta, GA, USA, 30004
Avanos Medical Inc is a medical technology company engaged in the development and commercialization of products for pain management and patient care. The company has two reportable segments: Specialty Nutrition Systems and Pain Management and Recovery. The Specialty Nutrition Systems segment provides enteral feeding and neonatal products. The Pain Management and Recovery segment offers surgical pain and recovery products, including pain pumps and radiofrequency ablation solutions for the treatment of chronic pain.
40GF Score

Get the complete analysis for AVNS

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$24.99
Price
$19.31
GF Value